CombiGene AB (publ) (COMBI.ST)
SEK 2.7
(-0.74%)
SEK 2.7
(-0.74%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 120.61 Million SEK | -23.77% |
| 2022 | 158.22 Million SEK | -4.81% |
| 2021 | 166.22 Million SEK | 109.31% |
| 2020 | 79.41 Million SEK | 81.23% |
| 2019 | 43.81 Million SEK | 24.78% |
| 2018 | 35.11 Million SEK | 331.45% |
| 2017 | 8.13 Million SEK | 66.47% |
| 2016 | 4.88 Million SEK | -55.38% |
| 2015 | 10.95 Million SEK | 75.39% |
| 2014 | 6.24 Million SEK | 876.79% |
| 2013 | 639.58 Thousand SEK | 7.55% |
| 2012 | 594.67 Thousand SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 100.65 Million SEK | -7.21% |
| 2024 Q1 | 108.47 Million SEK | -10.06% |
| 2023 Q3 | 128.24 Million SEK | -6.82% |
| 2023 Q2 | 137.63 Million SEK | -3.97% |
| 2023 Q4 | 120.61 Million SEK | -5.95% |
| 2023 FY | 120.61 Million SEK | -23.77% |
| 2023 Q1 | 143.33 Million SEK | -9.41% |
| 2022 Q2 | 165.49 Million SEK | 1.81% |
| 2022 Q3 | 170.2 Million SEK | 2.84% |
| 2022 Q4 | 158.22 Million SEK | -7.04% |
| 2022 FY | 158.22 Million SEK | -4.81% |
| 2022 Q1 | 162.55 Million SEK | -2.21% |
| 2021 FY | 166.22 Million SEK | 109.31% |
| 2021 Q4 | 166.22 Million SEK | 57.27% |
| 2021 Q3 | 105.69 Million SEK | -8.14% |
| 2021 Q2 | 115.06 Million SEK | 66.9% |
| 2021 Q1 | 68.94 Million SEK | -13.18% |
| 2020 FY | 79.41 Million SEK | 81.23% |
| 2020 Q3 | 68.79 Million SEK | 47.75% |
| 2020 Q2 | 46.56 Million SEK | 21.49% |
| 2020 Q4 | 79.41 Million SEK | 15.43% |
| 2020 Q1 | 38.32 Million SEK | -12.54% |
| 2019 Q4 | 43.81 Million SEK | 33.08% |
| 2019 FY | 43.81 Million SEK | 24.78% |
| 2019 Q2 | 25.61 Million SEK | -16.67% |
| 2019 Q3 | 32.92 Million SEK | 28.52% |
| 2019 Q1 | 30.74 Million SEK | -12.45% |
| 2018 Q1 | 7.77 Million SEK | -4.46% |
| 2018 Q2 | 5.68 Million SEK | -26.85% |
| 2018 Q4 | 35.11 Million SEK | -31.88% |
| 2018 FY | 35.11 Million SEK | 331.45% |
| 2018 Q3 | 51.54 Million SEK | 806.24% |
| 2017 Q1 | 17.02 Million SEK | 248.26% |
| 2017 Q3 | 11.32 Million SEK | -14.84% |
| 2017 Q4 | 8.13 Million SEK | -28.12% |
| 2017 FY | 8.13 Million SEK | 66.47% |
| 2017 Q2 | 13.29 Million SEK | -21.91% |
| 2016 FY | 4.88 Million SEK | -55.38% |
| 2016 Q3 | 8.15 Million SEK | -20.6% |
| 2016 Q1 | 12.54 Million SEK | 14.43% |
| 2016 Q4 | 4.88 Million SEK | -40.03% |
| 2016 Q2 | 10.26 Million SEK | -18.12% |
| 2015 Q4 | 10.95 Million SEK | -12.95% |
| 2015 Q2 | 14.1 Million SEK | 167.34% |
| 2015 Q1 | 5.27 Million SEK | -15.56% |
| 2015 FY | 10.95 Million SEK | 75.39% |
| 2015 Q3 | 12.58 Million SEK | -10.73% |
| 2014 Q4 | 6.24 Million SEK | 0.0% |
| 2014 FY | 6.24 Million SEK | 876.79% |
| 2014 Q1 | - SEK | 0.0% |
| 2013 FY | 639.58 Thousand SEK | 7.55% |
| 2012 FY | 594.67 Thousand SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 118.45 Million SEK | -1.825% |
| Ziccum AB (publ) | 14.97 Million SEK | -705.584% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -501.826% |
| BioArctic AB (publ) | 1.18 Billion SEK | 89.831% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -93.36% |
| Mendus AB (publ) | 755.95 Million SEK | 84.045% |
| Genovis AB (publ.) | 288.85 Million SEK | 58.245% |
| Intervacc AB (publ) | 259.61 Million SEK | 53.541% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -187.452% |
| Active Biotech AB (publ) | 44 Million SEK | -174.118% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 56.73% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -94.06% |
| Aptahem AB (publ) | 63.02 Million SEK | -91.372% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 75.695% |
| Kancera AB (publ) | 65.64 Million SEK | -83.739% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 65.67% |
| Fluicell AB (publ) | 9.34 Million SEK | -1191.349% |
| Saniona AB (publ) | 64.14 Million SEK | -88.036% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -258.943% |
| Biovica International AB (publ) | 131.4 Million SEK | 8.216% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -127.634% |
| AcouSort AB (publ) | 34.51 Million SEK | -249.468% |
| Xintela AB (publ) | 18.39 Million SEK | -555.678% |
| Abliva AB (publ) | 87.49 Million SEK | -37.844% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 84.134% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 90.415% |
| OncoZenge AB (publ) | 20.34 Million SEK | -492.979% |
| Amniotics AB (publ) | 26.08 Million SEK | -362.363% |
| 2cureX AB (publ) | 16.62 Million SEK | -625.486% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -1884.729% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 93.654% |
| Camurus AB (publ) | 1.9 Billion SEK | 93.678% |
| Corline Biomedical AB | 100.1 Million SEK | -20.485% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 31.904% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 14.214% |
| I-Tech AB | 152.44 Million SEK | 20.881% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 88.153% |
| Cyxone AB (publ) | 43.65 Million SEK | -176.285% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | -53.271% |
| Biosergen AB | 7.2 Million SEK | -1574.934% |
| Cantargia AB (publ) | 223.71 Million SEK | 46.086% |
| NextCell Pharma AB | 81.28 Million SEK | -48.376% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 84.239% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -299.734% |
| Nanologica AB (publ) | 77.42 Million SEK | -55.771% |
| SynAct Pharma AB | 228.01 Million SEK | 47.104% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -350.667% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -455.742% |
| LIDDS AB (publ) | 17.65 Million SEK | -583.161% |
| Lipum AB (publ) | 12.11 Million SEK | -895.97% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 91.386% |
| Alzinova AB (publ) | 123.18 Million SEK | 2.092% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 49.403% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -1326.517% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | -41.519% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -711.164% |
| Simris Alg AB (publ) | 174.55 Million SEK | 30.902% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 44.428% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 81.544% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | -38.52% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -323.081% |